Comparing two immune treatments for stem cell transplant patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares two drugs, ATLG and ATG, to see which one helps rebuild the immune system better after a stem cell transplant for blood cancer. It aims to improve recovery and reduce complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a confirmed blood cancer diagnosis.
- This is your first time receiving a stem cell transplant from a donor.
- You are in fairly good health overall (ECOG score 0-2).
- Your heart, liver, kidneys, and lungs are functioning well enough for the transplant.
- You are able to follow the study plan and provide written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
This trial tests whether adding dexamethasone, intravenous immunoglobulin, and extra donor cells can lower donor-specific antibodies in people receiving half-matched stem cell transplants. The goal is to help more patients safely get a transplant when fully matched donors aren't available.
This trial tests whether giving anti-thymocyte globulin (ATG) based on a person's own body chemistry can reduce side effects and improve outcomes in stem cell transplants. It is for people with certain blood cancers who are in their first or second remission.
This trial tests a personalized approach to using ATG (a medicine that reduces immune rejection) in patients receiving stem cell transplants from unrelated donors for blood cancers. The goal is to improve transplant success while reducing side effects by tailoring ATG doses to individual patients.
This trial tests a personalized dosing method for a medicine called ATG, which helps prevent your body from rejecting a donor stem cell transplant. It is for people with blood cancers who need a transplant from an unrelated donor.
This trial tests a new combination of medicines to prevent graft-versus-host disease (GVHD) in patients with leukemia or myelodysplastic syndromes receiving a stem cell transplant from a half-matched donor. It aims to see if using less anti-thymocyte globulin (ATG) plus a simpler post-transplant cyclophosphamide (PTCy) regimen works as well as standard care with fewer side effects.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.